“Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry”, J of Skin, vol. 8, no. 6, p. s450, Nov. 2024, doi: 10.25251/skin.8.supp.450.